drugset / Trial / NCT05999799

A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT05999799

Phase 2 Terminated 161 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is parallel group, placebo-controlled dose-ranging study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of GSK1070806 in adult participants with moderate to severe Atopic Dermatitis (AtD), who have previously been treated with medicated topical treatments or a biologic therapy.

Timeline

Start
2023-11-16
Primary completion
2025-07-23
Completion
2025-07-23

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK1070806 Monoclonal antibody Subcutaneous

Indications